2024
Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disorders
Daccache J, Park E, Junejo M, Abdelghaffar M, Hwang E, Mohanty C, Singh C, Wang G, Wheeler J, Shields B, Nelson C, Wang Y, Damsky W. Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disorders. Journal Of Allergy And Clinical Immunology 2024, 154: 1216-1231. PMID: 39098508, PMCID: PMC11560686, DOI: 10.1016/j.jaci.2024.07.021.Peer-Reviewed Original ResearchCutaneous sarcoidosisNecrobiotic xanthogranulomaGranulomatous disorderGranuloma annulareNecrobiosis lipoidicaImmune activationMacrophage activationCutaneous granulomatous disordersPattern of immune activationType 2 immune activationActivation of Th1Pattern of Th1Alternative macrophage activationAlternative macrophage polarizationAlteration of extracellular matrixPatterns of macrophage activationCases of CSPredominant inflammationExtracellular matrix alterationsTh17 immunityT-helperTh2 polarizationIL-32Histological changesChemokine signaling
2023
Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis
Hwang E, Abdelghaffar M, Shields B, Damsky W. Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis. JID Innovations 2023, 3: 100220. PMID: 37719661, PMCID: PMC10500476, DOI: 10.1016/j.xjidi.2023.100220.Peer-Reviewed Original ResearchDisease pathogenesisCutaneous granulomatous disordersLow-quality evidenceRepository corticotropin injectionOutcome of treatmentImmunomodulatory medicationsPulmonary sarcoidosisCutaneous sarcoidosisGranulomatous disorderNecrobiosis lipoidicaCorticotropin injectionMacrophage accumulationGranuloma annulareGranulomatous diseaseCutaneous granulomatous diseasesTargeted therapyDrug AdministrationMolecular pathogenesisNew treatmentsSystematic reviewPathogenesisTherapyDistinct diseasesTherapeutic innovationsDisease
2019
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.Peer-Reviewed Original ResearchConceptsGranuloma annulareCutaneous sarcoidosisPathway activationCutaneous granulomatous disordersRecalcitrant cutaneous sarcoidosisSkin biopsy specimensSignal regulatory protein αJAK-STAT pathway activationTranscription (JAK/STAT) pathway activationRegulatory protein αRecalcitrant sarcoidosisSarcoidosis activityDisease remissionConsecutive patientsGranulomatous disorderProspective evaluationBiopsy specimensHistologic resolutionSkin biopsiesMean improvementSarcoidosisImmunohistochemical analysisJAK inhibitorsJAK inhibitionPatients
2018
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. New England Journal Of Medicine 2018, 379: 2540-2546. PMID: 30586518, PMCID: PMC6351852, DOI: 10.1056/nejmoa1805958.Peer-Reviewed Original ResearchConceptsCutaneous sarcoidosisPathogenesis of sarcoidosisSkin lesion samplesJAK inhibitor tofacitinibHistologic remissionSystemic glucocorticoidsImmunohistochemical testingImmunohistochemical examinationInhibitor tofacitinibSarcoidosisSkin diseasesPatientsLesion samplesJAK-STATJanus kinaseTranscription (STAT) signalingSequencing of RNASignal transducerTreatmentMolecular analysisRemissionMedicationsTofacitinibGlucocorticoidsPathogenesis